Cell & gene therapy (C&GT) is complex, expensive and lacks standardization.

How do you effectively evaluate and make informed decisions to identify a winning viral vector production strategy to improve the accessibility & affordability of C&GT?

We are thrilled to announce our Fast Facts video with Cell & Gene Insights, where our expert Andrea Vervoort, Technical Lead, breaks down key cost drivers of AAV manufacturing and the commercial impacts of incorporating Virica’s Viral Sanitizers (VSETM) using Biopharm’s BioSolve Bioprocess modelling.

Click here to view our latest bioprocess modelling data in a Fast Facts video on Cell & Gene Insights!